10-Q: Berto Acquisition Reports Q3 Net Income, Eyes OnMed Merger

Berto Acquisition Corp. reported a net income of $3.17 million for Q3 2025 and announced a non-binding letter of intent for a potential business combination with OnMed LLC.

Summary

• Berto Acquisition Corp., a Special Purpose Acquisition Company (SPAC), reported a net income of $3,167,377 for the three months ended September 30, 2025, and $5,010,826 for the nine months ended September 30, 2025.
• The primary source of income was investment income from funds held in the Trust Account, totaling $3,343,285 for the quarter and $5,427,225 for the nine months.
• The company has entered into a non-binding letter of intent (LOI) for a potential business combination with OnMed LLC, a developer of healthcare infrastructure solutions.
• As of September 30, 2025, cash stood at $325,010, and investments in the Trust Account were $305,577,225.
• Liquidity is deemed sufficient for at least one year from the financial statement issuance date, supported by funds outside the Trust Account and the Sponsor's commitment.
• General and administrative expenses were $179,492 for the quarter and $426,577 for the nine months, including administrative services paid to the Sponsor.

Sentiment

Score: 7

Explanation: The company reported positive net income from its Trust Account investments, which is expected for a SPAC. The significant positive is the announcement of a non-binding LOI with OnMed LLC, indicating concrete progress towards a business combination, which is the primary goal of a SPAC. However, the LOI is non-binding, and macroeconomic risks persist.

Positives

• Reported net income of $3,167,377 for the three months ended September 30, 2025, and $5,010,826 for the nine months ended September 30, 2025.
• Significant investment income from the Trust Account, totaling $3,343,285 for the quarter and $5,427,225 for the nine months.
• Announcement of a non-binding letter of intent (LOI) with OnMed LLC for a potential business combination, indicating progress towards its primary objective.
• Sufficient liquidity to fund working capital needs for at least one year, supported by cash outside the Trust Account and the Sponsor's commitment.
• Full exercise of the underwriters' over-allotment option on May 1, 2025, indicating strong initial demand for the IPO.

Negatives

• Accumulated deficit increased to $(11,490,730) as of September 30, 2025, from $(738,290) at December 31, 2024, primarily due to remeasurement of ordinary shares subject to possible redemption.
• Ongoing general and administrative expenses, totaling $179,492 for the quarter and $426,577 for the nine months, reduce the cash available outside the Trust Account.
• The company has not yet commenced operations and will not generate operating revenues until after the completion of an Initial Business Combination.
• The LOI with OnMed LLC is non-binding, and there is no assurance that a definitive agreement will be executed or that the proposed transaction will be consummated.

Risks

• No assurance that the company will be able to successfully effect an Initial Business Combination within the Completion Window (by May 1, 2027).
• The longer the company holds investments in the Trust Account, the higher the risk of being deemed an investment company for purposes of the Investment Company Act.
• Proceeds deposited in the Trust Account could become subject to the claims of the company's creditors, which could have priority over the claims of Public Shareholders.
• Various macroeconomic, geopolitical, and regulatory uncertainties (e.g., inflation, trade/tariffs, interest rates, geopolitical conflicts) could negatively impact economic growth and financial markets, adversely affecting the search for a target business.
• Changes in international trade policies, tariffs, and treaties could materially impact a target company's business and financial performance, potentially reducing the pool of suitable targets or making transactions more costly/risky.
• If an Initial Business Combination is not completed within the Completion Window, holders of warrants will not receive any funds from the Trust Account or other assets, and the warrants may expire worthless.
• The exercise of warrants could dilute the ownership of existing shareholders.
• The company may need Working Capital Loans from the Sponsor or affiliates to finance transaction costs, and there is no obligation for them to provide such loans.
• As an emerging growth company, electing to delay the adoption of new accounting standards may make the company's financial statements not comparable to other public companies.

Future Outlook

The company's primary objective is to complete an Initial Business Combination, with a non-binding letter of intent already signed with OnMed LLC. It will continue to incur increased expenses as a public company and for due diligence related to potential business combinations. The company aims to capitalize on transformative opportunities in sustainability and innovation, focusing on new energy, circular economy, and agricultural/food technologies in North America and Europe. Management believes current liquidity is sufficient for at least one year to fund working capital needs.

Management Comments

• "Our management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Sponsor Private Placement Warrants, although substantially all of the net proceeds of the Initial Public Offering are intended to be generally applied toward consummating an Initial Business Combination."
• "We are strategically positioned to capitalize on transformative opportunities, focusing on sectors that are pivotal to advancing sustainability and innovation."
• "Our investment thesis prioritizes target businesses primarily in North America and Europe, with a keen interest in new energy businesses, circular economy initiatives, and innovative agricultural and food technologies."
• "Management has determined that our current liquidity... is sufficient to fund us the working capital needs through a minimum of one year from the date of issuance of these unaudited condensed financial statements."

Industry Context

Berto Acquisition Corp. operates as a Special Purpose Acquisition Company (SPAC), a common vehicle for private companies to go public. The stated investment thesis focuses on "sustainability and innovation," specifically "new energy businesses, circular economy initiatives, and innovative agricultural and food technologies" in North America and Europe. This aligns with broader market trends favoring ESG (Environmental, Social, and Governance) investments and technological advancements in critical sectors. The announcement of a non-binding LOI with OnMed LLC, a healthcare infrastructure solutions developer, suggests a potential pivot or expansion within the "innovation" aspect of their thesis, potentially tapping into the growing digital health and accessible healthcare market. The SPAC market has seen increased scrutiny and redemptions in recent years, making successful business combinations crucial for investor confidence.

Comparison to Industry Standards

• As a Special Purpose Acquisition Company (SPAC) that has not yet completed its initial business combination, direct operational comparisons to established industry players are not applicable.
• The company's performance is currently measured by its ability to generate interest income from its Trust Account and manage its general and administrative expenses while actively seeking a suitable target.
• The interest income generated from the Trust Account is a standard feature for SPACs, reflecting prevailing interest rates on U.S. government securities or money market funds.
• The administrative expenses are also typical for a SPAC in its pre-combination phase.
• The key benchmark for Berto Acquisition Corp. at this stage is its progress in identifying and negotiating a business combination within its Completion Window, which is May 1, 2027.
• The announcement of a non-binding LOI with OnMed LLC indicates progress towards this primary objective, which is a positive development for a SPAC.

Management Changes

Corporate Governance

Related Party Transactions

• **Founder Shares**: The Sponsor and its affiliates, along with Meteora Capital LLC, purchased 7,503,750 Founder Shares for a nominal amount.
• **Administrative Services**: The company agreed to reimburse the Sponsor or an affiliate $15,000 per month for office space, utilities, and administrative support, with payments deferred until the closing of an Initial Business Combination. An outstanding balance of $75,000 was accrued as of September 30, 2025.
• **Reimbursement of Out-of-Pocket Expenses**: The Sponsor, executive officers, and directors, or any of their respective affiliates, will be reimbursed for out-of-pocket expenses incurred in connection with identifying potential target businesses and performing due diligence.
• **Working Capital Loans**: The Sponsor or an affiliate of the Sponsor, or the company's officers and directors may provide non-obligatory Working Capital Loans to finance transaction costs. Up to $1.5 million of such loans may be convertible into warrants of the post-Initial Business Combination entity at $1.00 per warrant. No borrowings were outstanding as of September 30, 2025.
• **Promissory Note**: The Sponsor loaned the company approximately $222,000 under a non-interest bearing promissory note, which was fully repaid on May 1, 2025.
• **Consulting Agreement with Meteora**: Meteora Capital LLC provided consulting services and received 300,000 Founder Shares for an aggregate purchase price of $1,043 (fair value estimated at $150,000).
• **CFO Services Agreement with Meteora**: A quarterly fee of $37,500 is paid to Meteora for making Vikas Mittal available to serve as Chief Financial Officer, commencing July 2025. An outstanding balance of $37,500 was accrued as of September 30, 2025.

Stakeholder Impact

• **Shareholders (Public)**: Potential for value creation if the OnMed LLC business combination is successful; risk of warrant expiration worthless if no combination occurs; redemption rights available upon business combination or liquidation.
• **Shareholders (Founder/Sponsor)**: Founder Shares are subject to lock-up periods and voting agreements; potential for significant returns if the business combination is successful; risk of losing investment if no combination.
• **Underwriters**: Entitled to deferred underwriting fees of approximately $11.7 million upon completion of a business combination; received Underwriter Private Placement Warrants.
• **OnMed LLC**: Potential to become a publicly traded entity through the proposed transaction, gaining access to public markets and capital.
• **Employees (Management)**: Compensation and potential for warrant conversion if Working Capital Loans are provided, aligning incentives with business combination success.

Next Steps

• Negotiate and enter into a definitive agreement for the potential business combination with OnMed LLC.
• Complete due diligence for the proposed transaction.
• Seek board and equity holder approval for the proposed transaction.
• Obtain necessary regulatory approvals for the proposed transaction.
• File a registration statement (Form S-1, S-3, F-1, or F-3) for the ordinary shares issuable upon exercise of Public Warrants within 20 business days after the closing of the Initial Business Combination.
• Maintain the effectiveness of the registration statement for warrants until they expire or are redeemed.

Key Dates

Recommendation

Berto Acquisition Corp. has made tangible progress by announcing a non-binding LOI with OnMed LLC, which is a positive step for a SPAC. The company also reported expected net income from its Trust Account. However, the LOI is non-binding, and the successful completion of a definitive agreement and the business combination remains uncertain and subject to various conditions and approvals. Investors should hold while monitoring further developments regarding the proposed transaction and the terms of any definitive agreement. The inherent risks of SPACs, including the potential for warrants to expire worthless if no combination occurs, warrant a cautious "hold" stance rather than a "buy" until more certainty emerges.

Keywords

SPAC, Special Purpose Acquisition Company, Business Combination, Merger, Acquisition, OnMed LLC, Healthcare Infrastructure, Trust Account, Warrants, Initial Public Offering, Q3 2025, Financial Results, SEC Filing, TACOU